Organon Secures US Food and Drug Administration Approval Expanding Indications for Tofidence (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
BLA FilingapprovedTofidencePositive
AI Analysis
Summary
Organon announced FDA approval of a supplemental Biologics License Application for Tofidence (tocilizumab-bavi), expanding its approved indications to include Cytokine Release Syndrome and Pediatric COVID-19.
Outcome Details
FDA approval of supplemental Biologics License Application (sBLA) expanding indications for Tofidence to include Cytokine Release Syndrome and Pediatric COVID-19
Importance:8/10
Sentiment:
0.85
FDA approvalindication expansionsBLAbiologicstocilizumab
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on June 10, 2026 2:06 AM